The combination of medications against PD-1, Lag-3 and TIM-3 molecules can prevent sustainable skin cancer development. This conclusion was the scientists of the Mophet Cancer Center. The results of the work were published in the "Cancer Immuneration" (JITC) magazine.
A aggressive type of melanoma is an aggressive type of cancer that develops from melanches. These cells produce Melani pigment responsible for skin, eyes and hair color.
The main method of treatment is immunterapy, which intensifies the natural defense mechanisms of the body against the tumor. However, most patients are or does not respond to treatment or have a repetition of disease.
As part of the study, scientists have tested the effect of triple therapy, which simultaneously blocks several immune test points that can use the tumor to avoid the immune system attack. It turned out that the combination of PD-1, LAG-3 and TIM-3 inhibitors restores the work of immune cells even when standard treatment is not working. In some cases, this treatment has led to mice near the tumor of complete regression.
"Tim-3 is often found in immune cells that are very exhausted to fight cancer," Smali explained. "By blocking TIM-3 with PD-1 and LAG-3, we were able to make a more powerful immune response to this difficult treated cancer."
The researchers stressed that the combined drug was not toxic.
"Our results are opening a new way for the treatment of patients with melanoma, who have many limited treatment options," said scientists.
Translation of: Euromedia24.com
